Journals / Molecular Imaging and Radionuclide Therapy / 2019 / Cilt: 28 - Sayı: 2

Comparison of SUVmax Values Obtained from F-18 FDG PET/CT and Cell-free DNA Levels Measured from Plasma in Oncology Patients

Onkoloji Hastalarında F-18 FDG PET/BT’de Elde Edilen SUVmaks Değerleri ile Plazmadan Ölçülen Cell-free DNA Seviyelerinin Karşılaştırılması

Pages
46–52
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Comparison of cfDNA levels obtained from plasma and quantitative parameters from PET/CT images of oncology patients in detailed advanced studies with larger patient series are required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to compare the quantitative value of standardized uptake value (SUV) SUVmax obtained from F-18 FDG positron emission tomography/computed tomography (PET/CT) imaging of oncology patients with the cell-free DNA (cfDNA) amounts measured in plasma of patients and thus investigate if cfDNA is a significant marker to identify the presence of malignancy in the early period.Methods: A total of 184 patients were included in the study.
📊
Key Findings & Data:SUVmax and cfDNA quantities were assessed.Results: There was no statistically significant difference in plasma cfDNA values between patient and control groups.
💡
Conclusion & Impact:Comparison of cfDNA levels obtained from plasma and quantitative parameters from PET/CT images of oncology patients in detailed advanced studies with larger patient series are required.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to compare the quantitative value of standardized uptake value (SUV) SUVmax obtained from F-18 FDG positron emission tomography/computed tomography (PET/CT) imaging of oncology patients with the cell-free DNA (cfDNA) amounts measured in plasma of patients and thus investigate if cfDNA is a significant marker to identify the presence of malignancy in the early period.Methods: A total of 184 patients were included in the study. The clinical, histopathologic, laboratory and treatment parameters were extracted from patient files. SUVmax and cfDNA quantities were assessed.Results: There was no statistically significant difference in plasma cfDNA values between patient and control groups. The comparison of SUVmax and cfDNA values in the study showed that there was a weak correlation between SUVmax and cfDNA. There was a significant difference between tumor size and SUVmax values. However, there was no statistically significant difference between tumor size and cfDNA.Conclusion: cfDNA measurements in the blood as a screening test have provided hope for early diagnosis and monitoring of cancer patients. Comparison of cfDNA levels obtained from plasma and quantitative parameters from PET/CT images of oncology patients in detailed advanced studies with larger patient series are required.

Özet

Amaç: Bu çalışmanın amacı, onkoloji hastalarında F-18 FDG pozitron emisyon tomografi/bilgisayarlı tomografi (PET/BT) görüntülemelerinden elde edilen standart tutulum değeri (SUV) SUVmaks’ın, hastaların plazmalarında ölçülen serbest DNA (cfDNA) miktarları ile kantitatif değerini karşılaştırmak ve böylece cfDNA’nın erken dönemde malignitenin varlığını tanımlamak için önemli bir belirteç olup olmadığını araştırmaktır.Yöntem: Çalışmaya toplam 184 hasta dahil edildi. Klinik durum, histopatolojik, laboratuvar ve tedavi parametreleri hasta dosyalarından araştırıldı. SUVmaks değeri ve cfDNA miktarları karşılaştırıldı.Bulgular: Hasta ve kontrol grubu arasında plazma cfDNA değerleri arasında istatistiksel olarak anlamlı fark yoktu. Araştırmada SUVmaks ve cfDNA değerlerinin karşılaştırılmasının sonucunda SUVmaks ve cfDNA arasında zayıf bir korelasyon vardı. Tümör boyutu ve SUVmaks değerleri arasında anlamlı bir fark bulundu. Bununla birlikte, tümör boyutu ve cfDNA arasında belirgin bir istatistiksel farklılık saptanmadı.Sonuç: Basit bir tarama testi olarak kullanılabilecek olan cfDNA ölçümleri kanser hastalarının erken tanı ve takiplerinde umut vaad etmektedir. Bu nedenle onkoloji hastalarının plazmalarından elde edilen cfDNA düzeyi ve PET/BT görüntülerinden elde edilen kantitatif parametrelerin karşılaştırıldığı daha büyük hasta serilerinde ve detaylı ileri çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ÇELİK, F., TAN, Y. Z., ÖZDEMİR, S., SILAN, F. (2022). Comparison of SUVmax Values Obtained from F-18 FDG PET/CT and Cell-free DNA Levels Measured from Plasma in Oncology Patients. Molecular Imaging and Radionuclide Therapy, Cilt: 28 - Sayı: 2, 46–52. https://ajindex.com/articles/581602

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Ca Cancer J Clin 2015;65:87-108.
  2. Papathanassiou D, Bruna-Muraille C, Liehn JC, Nguyen TD, Curé H. Positron Emission Tomography in Oncology: Present and future of PET and PET/CT. Crit Rev Oncol Hematol 2009;72:239-254.
  3. Blodgett TM, McCook BM, Federle MP. Positron Emission Tomography/ Computed Tomography: Protocol Issues and Options. Semin Nucl Med 2006;36:157-168.
  4. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23:707-712.
  5. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.
  6. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.
  7. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? CancerTreat Rev 2002;28:255-271.
  8. Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treatt 2006;99:63-69.
  9. Fleischhacker M, Schmidt B. Circulating nucleicacids (CNAs) and cancer-A survey. Biochimica et Biophysica Acta 2007;1775:181-232.
  10. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma Cell-free DNA in Ovarian Cancer: An Independent Prognostic Biomarker. Cancer 2010;116:1918-1925. 10. Herrera LJ, Raja S, Gooding WE, El- Hefnawy T, Kelly L, Luketich JD, Godfrey TE. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005;51:113-118. 11. Chen AY, Braunstein GD, Anselmo MS, Jaboni JA, Viloria FT, Neidich JA, Li X, Kammesheidt A. Mutation detection with a liquid biopsy 96 mutation assay in cancer patients and healthy donors. Cancer Transl Med 2017;3:39-45. 12. Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S, Lee S. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res 2014;86:136-142. 13. Esposito A, Criscitiello C, Trapani D, Curigliano G. The emerging role of “liquid biopsies”, circ